First New Agent for CLL Patients Approved by the FDA since 2001 - March 21, 2008 - Cephalon

CEAT Ltd, the flagship company of the 13,500 crore RPG Group and one of India’s leading tyre manufacturers has today signed an agreement with M/s. Ashford InfoTech Limited for development of a vacant portion of about 7 acres of land located at Village Road in Bhandup, Mumbai. The proceeds of the... - March 12, 2008 - RPG

The FDA has approved PRISTIQ (desvenlafaxine), an SNRI, to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping PRISTIQ to wholesalers beginning in the second quarter of 2008. - March 01, 2008 - Wyeth Pharmaceuticals

Anavex Life Sciences Corp. achieved significant development of its lead drug candidates and growth of its management and scientific teams during 2007. - January 24, 2008 - Anavex Life Sciences Corp.

ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. - January 16, 2008 - Anavex Life Sciences Corp.

Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits. - January 16, 2008 - Anavex Life Sciences Corp.

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) announces the appointment of Dr. Cameron Durrant to its Board of Directors. - January 16, 2008 - Anavex Life Sciences Corp.

Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals

Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan Pharmaceuticals... - January 09, 2008 - Samaritan Pharmaceuticals

The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health is... - January 03, 2008 - Samaritan Pharmaceuticals

Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals

The annual art camp by the RPG Academy of Art concluded with a warm brunch at the Marve beach house today. Pristine white was the theme of the locale and the breezy touch of sea winds along with the live band playing some groovy numbers got the enchantment heightened. After the week-long camp, the participating... - December 30, 2007 - RPG

•Rs. 391 Crores win in Abu Dhabi; Largest single win ever, in dollar value terms, for KEC •Rs. 246 crores turnkey contract in Algeria - December 01, 2007 - RPG

•Rs. 260 Crores Turnkey contract in Saudi Arabia •Rs. 140 Crores Turnkey contract in Namibia - December 01, 2007 - RPG

In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals

Company Executives Offer “Crystal Ball” Predictions. VP of Research Discusses Need for New Approaches in Anti-Infectives. - November 22, 2007 - NovaBay Pharmaceuticals, Inc.

IRG to Communicate the Company’s Clinical Development Programs - November 21, 2007 - NovaBay Pharmaceuticals, Inc.

In a comparison study between schizophrenia treatments INVEGA™ (paliperidone) Extended-Release Tablets and SEROQUEL® (quetiapine), Invega patients saw schizophrenia symptom improvements as early as five days into therapy and continued through the end of the two-week study period. Results were presented today at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida. - October 13, 2007 - Johnson & Johnson

Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals

Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals

Advaxis’ John Rothman Recognized as one of 20 Notable People in R&D - March 16, 2007 - Advaxis

In insomnia news, actor and insomnia sufferer, Cheryl Hines, joins the American Academy of Nurse Practitioners (AANP) Foundation to pull the covers off chronic insomnia. “Why Count on Sheep to Sleep?”, an educational initiative, supported by Sanofi-Aventis, raises awareness of sleep problems, causes of insomnia, and provides people with sleep solutions. Sleep disorders can be a serious medical condition characterized by difficulty falling asleep and staying asleep. - March 10, 2007 - Sanofi-Aventis

Pro-Tect, Inc. (PRTT.PK) announced today that it has entered into a licensing agreement with American Natural Technology Sciences (ANTS) for the marketing rights to Mitigator's® technology. - March 09, 2007 - Pro-Tect, Inc.

New Life Scientific, Inc. (OTCBB: NWLS), a company which specializes in the development of new biotechnology products and pharmaceuticals, announced today that it has transferred marketing rights to Atlan International(OTC: ATLI) of license agreement for two platform technologies (patent pending) that... - February 27, 2007 - New Life Scientific, Inc.

Instead of using the usual cancer-fighting modalities, surgery, chemotherapy, or radiation, researchers from a drug development company called Advaxis, have embarked on a novel approach to fighting cancer: Engaging the immune system to attack cancer in the same the way it would a flu vaccine, by creating... - February 27, 2007 - Advaxis

Carrington Laboratories, Inc. (Nasdaq: CARN) announced it has entered into a one-year endorsement and personal services agreement with racing legend Johnny Rutherford. The partnership provides a platform for Carrington to reach the rapidly growing and attractive racing enthusiast consumer market. Under... - February 17, 2007 - Carrington Laboratories

Pharma Trials International, Inc. a subsidiary of New Life Scientific, Inc. (OTCBB: NWLS), specializes in providing clinical trial services, market research, and services to enable pharmaceutical, biotech and medical device companies worldwide to conduct research and to obtain regulatory approval of... - February 01, 2007 - New Life Scientific, Inc.

After very successful pre-clinical trials for its lead product ‘Minozac,’ Neuromedix is planning further work on this promising Alzheimer’s treatment. - December 01, 2006 - Neuromedix Inc.

New Life Scientific, Inc (NWLS) a developmental biotech company whose core focus is to develop and commercialize novel biotech/pharmaceutical products including vaccines and stem cell based treatment modalities and to expand through our own research, collaborations, acquisitions and in-licensing, announced... - September 01, 2006 - New Life Scientific, Inc.

New Life Scientific, Inc (NWLS), today announced that at the special meeting of the Board of Directors a decision was made to re-evaluate its current progress and review its future options being considered include reviewing opportunities to acquire, license, and/or joint venture various medical, pharmaceutical,... - April 11, 2006 - New Life Scientific, Inc.

The newly appointed Board of Directors of HEE Corporation would like to summarize the recent reorganization activities that have taken place over the past few months. - February 16, 2006 - HEE Corporation

New Life Scientific, Inc. (OTCBB:NWLF - News) and Telomolecular Corp, have announced a strategic alliance to develop products that treat aging and age-related disease. New Life Scientific, Inc a company engaged in developing pharmaceutical products as well as managing PharmaTrials International (PTI),... - December 05, 2005 - New Life Scientific, Inc.